Early Cellular Responses of Prostate Carcinoma Cells to Sepantronium Bromide (YM155) Involve Suppression of mTORC1 by AMPK

The imidazolium compound YM155, first discovered as a potent inhibitor of Survivin, effectively kills many carcinomas in preclinical models. However, the upstream signaling mechanism triggered by YM155 remains unclear. Here we studied early signaling responses in vitro in prostate and renal cancer c...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Sci Rep
Main Authors: Danielpour, David, Gao, Zhaofeng, Zmina, Patrick M., Shankar, Eswar, Shultes, Benjamin C., Jobava, Raul, Welford, Scott M., Hatzoglou, Maria
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6687778/
https://ncbi.nlm.nih.gov/pubmed/31395901
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-019-47573-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados